- Home
- SXI vs KNSA Comparison
SXI vs KNSA Comparison
Compare SXI & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXI
- KNSA
- Stock Information
- Founded
- SXI 1955
- KNSA 2015
- Country
- SXI United States
- KNSA United Kingdom
- Employees
- SXI N/A
- KNSA N/A
- Industry
- SXI Industrial Machinery/Components
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- SXI Industrials
- KNSA Health Care
- Exchange
- SXI Nasdaq
- KNSA Nasdaq
- Market Cap
- SXI 2.0B
- KNSA 1.7B
- IPO Year
- SXI N/A
- KNSA 2018
- Fundamental
- Price
- SXI $181.26
- KNSA $26.75
- Analyst Decision
- SXI Strong Buy
- KNSA Strong Buy
- Analyst Count
- SXI 3
- KNSA 5
- Target Price
- SXI $200.33
- KNSA $33.60
- AVG Volume (30 Days)
- SXI 44.6K
- KNSA 454.3K
- Earning Date
- SXI 10-31-2024
- KNSA 10-29-2024
- Dividend Yield
- SXI 0.66%
- KNSA N/A
- EPS Growth
- SXI N/A
- KNSA N/A
- EPS
- SXI 6.14
- KNSA N/A
- Revenue
- SXI $720,635,000.00
- KNSA $338,930,000.00
- Revenue This Year
- SXI $6.59
- KNSA $58.95
- Revenue Next Year
- SXI $6.93
- KNSA $36.22
- P/E Ratio
- SXI $29.52
- KNSA N/A
- Revenue Growth
- SXI N/A
- KNSA 20.69
- 52 Week Low
- SXI $130.04
- KNSA $14.12
- 52 Week High
- SXI $191.18
- KNSA $27.92
- Technical
- Relative Strength Index (RSI)
- SXI 56.22
- KNSA 60.05
- Support Level
- SXI $174.92
- KNSA $23.33
- Resistance Level
- SXI $184.00
- KNSA $27.35
- Average True Range (ATR)
- SXI 3.26
- KNSA 0.93
- MACD
- SXI -0.12
- KNSA 0.26
- Stochastic Oscillator
- SXI 73.32
- KNSA 85.07
About SXI Standex International Corporation
Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. It has five reportable segments; Electronics; Engraving; Scientific; Engineering Technologies and Specialty Solutions. The maximum revenue is generated from its Electronics segment which is a component and value-added services provider of both sensing and switching technologies as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging among others. Geographically, it derives key revenue from the United States and the rest from Asia Pacific, Europe, Middle East and South Africa (EMEA), and other regions.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.